|[July 30, 2014]
Research and Markets: Fibromyalgia - Pipeline Review, H1 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/v8qbsn/fibromyalgia)
has announced the addition of the "Fibromyalgia
- Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Fibromyalgia, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Fibromyalgia and special features on late-stage and discontinued
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that allthe
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
Reasons to buy
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of
Identify and understand important and diverse types of therapeutics
under development for Fibromyalgia
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
Devise corrective measures for pipeline projects by understanding
Fibromyalgia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Eli Lilly and Company
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Collegium Pharmaceutical, Inc.
Concert Pharmaceuticals, Inc.
SWITCH Biotech LLC
EirGen Pharma Ltd.
Tonix Pharmaceuticals Holding Corp.
For more information visit http://www.researchandmarkets.com/research/v8qbsn/fibromyalgia
[ Back To TMCnet.com's Homepage ]